4/11/2023 0 Comments Finale 2014 download trial![]() ![]() ![]() 7, 2022 /PRNewswire/ - AbbVie (NYSE: ABBV) today announced new results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation (POAF) in cardiac surgery patients. Results were presented today as part of a late-breaking science session at the 2022 American Heart Association Scientific Sessions.Adverse Events (AEs) were numerically similar across treatment groups.Data showed relative risk reduction in specific study populations and overall lower rates of rehospitalization within 30 days compared to placebo.Primary endpoint was not met for the modified intent-to-treat (mITT) population however, clinical benefit observed in coronary artery bypass graft (CABG) patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |